Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 24;26:105. doi: 10.1186/s13075-024-03313-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Pfizer Inc and Navarro-Compán, Deodhar, Bahiri 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — Improvement events in fatigue, peripheral outcomes, and morning stiffness. Proportions of patients with ≥ 50% improvement in a fatigue (BASDAI Q1), b peripheral joint pain/swelling (BASDAI Q3), c enthesitis (BASDAI Q4), and d morning stiffness (mean of BASDAI Q5 and Q6) at each study visit. Vertical dotted line indicates week 16, after which all patients received open-label tofacitinib until week 48. The 50th percentile line is to facilitate interpretation of the results. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BID, twice daily; Q, question